Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Zhenkunxing 2025 Financial Report: Deepening Hardcore MRO, Achieving Dual Turning Points in Scale and Profitability, Entering a New Stage of High-Quality Growth

Zhenkunxing 2025 Financial Report: Deepening Hardcore MRO, Achieving Dual Turning Points in Scale and Profitability, Entering a New Stage of High-Quality Growth

格隆汇格隆汇2026/03/19 11:23
Show original
格隆汇 March 19|East Eight District March 19, China's leading MRO procurement service platform Zhenkunxing (ZKH.US) released its Q4 and full-year results for fiscal year 2025 before the US stock market opened. In Q4 2025, the company's GMV increased by 8.5% year-on-year to 2.92 billions RMB, revenue grew by 7.9% year-on-year to 2.56 billions RMB, the number of transaction customers reached nearly 74,000, up about 60% year-on-year, setting a new quarterly growth record; adjusted net profit reached 14.86 millions RMB, turning profitable at the quarterly level and achieving break-even for the half-year. The company expects GMV to achieve double-digit growth in Q1 2026. In terms of operational highlights, customer expansion, supply deepening, and AI efficiency improvement have become the core focus. Both large and SME customers maintained growth, with GMV of key industry customers generally increasing by more than 20% year-on-year, SME customer GMV also grew by more than 20% year-on-year, overseas business GMV increased by about 50% quarter-on-quarter, and the fulfillment and delivery network has expanded to 17 countries. By the end of 2025, platform SKU increased by 33% year-on-year to 23 millions, self-owned brand GMV grew by 21% year-on-year for the full year, with its proportion of total GMV rising to 8.3%; Q4 warehouse fee rate dropped by about 13% year-on-year, achieving double-digit declines for eight consecutive quarters. Zhenkunxing Chairman and CEO Chen Long stated that as the impact of business structure adjustments is gradually digested, the company has emerged from a period of phased adjustment. In the future, Zhenkunxing will continue to build long-term competitive barriers around product strength, delivery capability, and AI capability, driving the company into a more stable stage of high-quality growth, and striving to achieve full-year profitability in 2026.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals

October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)

路透社•2026/10/09 04:26
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals

Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low

UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.

智通财经•2026/10/09 03:53